MedAvail (MDVLQ) 10-Q 12 Aug 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2022	Aug. 09, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-36533
Entity Registrant Name	MEDAVAIL HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	90-0772394
Entity Address, Address Line One	6665 Millcreek Dr.
Entity Address, Address Line Two	Unit 1,
Entity Address, City or Town	Mississauga
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	L5N 5M4
City Area Code	905
Local Phone Number	812-0023
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	MDVL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		80,021,737
Entity Central Index Key	0001402479
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 29,202	$ 19,689
Restricted cash	676	400
Accounts receivable (net of allowance for doubtful accounts of $123 thousand for June 30, 2022, $66 thousand for December 31, 2021)	2,076	1,189
Inventories	5,620	3,916
Prepaid expenses and other current assets	3,376	2,191
Total current assets	40,950	27,385
Property, plant and equipment, net	6,366	5,692
Intangible assets, net	2,851	2,300
Right-of-use assets	2,433	2,538
Other assets	233	228
Total assets	52,833	38,143
Current liabilities:
Accounts payable	2,873	2,477
Accrued liabilities	1,696	1,530
Accrued payroll and benefits	3,047	2,733
Deferred revenue	91	83
Current portion of lease obligations	743	682
Total current liabilities	8,450	7,505
Long-term debt, net	9,679	9,538
Long-term portion of lease obligations	1,917	2,027
Total liabilities	20,046	19,070
Commitments and contingencies
Stockholders' deficit:
Common shares ($0.001 par value, 300,000,000 shares authorized, 70,609,972 and 32,902,048 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively)	71	33
Warrants	8,876	1,373
Additional paid-in-capital	247,598	216,685
Accumulated other comprehensive loss	(6,928)	(6,928)
Accumulated deficit	(216,830)	(192,090)
Total stockholders' equity	32,787	19,073
Total liabilities and stockholders' equity	$ 52,833	$ 38,143

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 123	$ 66
Common shares, par value (in USD per share)	$ 0.001	$ 0.001
Common shares, authorized (in shares)	300,000,000	300,000,000
Common shares, issued (in shares)	70,609,972	32,902,048
Common shares, outstanding (in shares)	70,609,972	32,902,048

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Total revenue	$ 11,184,000	$ 5,030,000	$ 20,298,000	$ 9,057,000
Cost of products sold and services:
Total cost of products sold and services	10,266,000	4,857,000	18,879,000	8,564,000
Operating expense:
Pharmacy operations	3,648,000	3,085,000	7,578,000	5,678,000
General and administrative	6,100,000	5,737,000	12,642,000	11,413,000
Selling and marketing	2,307,000	1,613,000	4,612,000	3,147,000
Research and development	281,000	201,000	774,000	369,000
Total operating expense	12,336,000	10,636,000	25,606,000	20,607,000
Operating loss	(11,418,000)	(10,463,000)	(24,187,000)	(20,114,000)
Other gain (loss), net	0	38,000	0	199,000
Interest income	0	27,000	1,000	67,000
Interest expense	(276,000)	(66,000)	(530,000)	(68,000)
Loss before income taxes	(11,694,000)	(10,464,000)	(24,716,000)	(19,916,000)
Income tax expense	(24,000)	0	(24,270)	0
Net loss	(11,718,000)	(10,464,000)	(24,740,000)	(19,916,000)
Comprehensive loss	$ (11,718,000)	$ (10,464,000)	$ (24,740,000)	$ (19,916,000)
Net loss per share - basic (in USD per share)	$ (0.17)	$ (0.32)	$ (0.48)	$ (0.61)
Net loss per share - diluted (in USD per share)	$ (0.17)	$ (0.32)	$ (0.48)	$ (0.61)
Weighted average shares outstanding - basic (in shares)	69,356,723	32,546,395	51,239,994	32,493,468
Weighted average shares outstanding - diluted (in shares)	69,356,723	32,546,395	51,239,994	32,493,468
Pharmacy and hardware revenue
Revenue:
Total revenue	$ 10,930,000	$ 4,725,000	$ 19,944,000	$ 8,506,000
Cost of products sold and services:
Total cost of products sold and services	10,151,000	4,679,000	18,714,000	8,205,000
Service revenue
Revenue:
Total revenue	254,000	305,000	354,000	551,000
Cost of products sold and services:
Total cost of products sold and services	$ 115,000	$ 178,000	$ 165,000	$ 359,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands		Total	Common Shares	Preferred Shares		Warrants	Additional Paid-in-Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Common Stock, Balance at beginning of period (in shares) at Dec. 31, 2020			31,816,020
Balance at beginning of period at Dec. 31, 2020		$ 61,067	$ 32	$ 0	[1]	$ 2,614	$ 213,624	$ (148,275)	$ (6,928)
Preferred Stock, Balance at beginning of period (in shares) at Dec. 31, 2020	[1]			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(19,916)						(19,916)
Exercise of options (in shares)			144,101
Exercise of options		241					241
Exercise of warrants (in shares)			623,613
Exercise of warrants		124	$ 1			(1,129)	1,252
Share-based compensation		583					583
Common Stock, Balance at end of period (in shares) at Jun. 30, 2021			32,583,734
Balance at end of period at Jun. 30, 2021		42,099	$ 33	$ 0	[1]	1,485	215,700	(168,191)	(6,928)
Preferred Stock, Balance at end of period (in shares) at Jun. 30, 2021	[1]			0
Common Stock, Balance at beginning of period (in shares) at Mar. 31, 2021			31,939,898
Balance at beginning of period at Mar. 31, 2021		52,081	$ 32	$ 0	[1]	2,579	214,125	(157,727)	(6,928)
Preferred Stock, Balance at beginning of period (in shares) at Mar. 31, 2021	[1]			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(10,464)						(10,464)
Exercise of options (in shares)			23,177
Exercise of options		40					40
Exercise of warrants (in shares)			620,659
Exercise of warrants		119	$ 1			(1,094)	1,212
Share-based compensation		323					323
Common Stock, Balance at end of period (in shares) at Jun. 30, 2021			32,583,734
Balance at end of period at Jun. 30, 2021		$ 42,099	$ 33	$ 0	[1]	1,485	215,700	(168,191)	(6,928)
Preferred Stock, Balance at end of period (in shares) at Jun. 30, 2021	[1]			0
Common Stock, Balance at beginning of period (in shares) at Dec. 31, 2021		32,902,048	32,902,048
Balance at beginning of period at Dec. 31, 2021		$ 19,073	$ 33	$ 0	[1]	1,373	216,685	(192,090)	(6,928)
Preferred Stock, Balance at beginning of period (in shares) at Dec. 31, 2021	[1]			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(24,740)						(24,740)
Issuance of common shares (in shares)			37,647,055
Issuance of common shares		37,201	$ 38				37,163
Issuance of warrants		$ 0				7,503	(7,503)
Shares issued for vested RSUs (in shares)			6,874
Exercise of options (in shares)		0
Exercise of warrants (in shares)		0
Issuance of common shares under employee stock purchase plan (in shares)			53,995
Issuance of common shares under employee stock purchase plan		$ 77					77
Share-based compensation		$ 1,176					1,176
Common Stock, Balance at end of period (in shares) at Jun. 30, 2022		70,609,972	70,609,972
Balance at end of period at Jun. 30, 2022		$ 32,787	$ 71	$ 0	[1]	8,876	247,598	(216,830)	(6,928)
Preferred Stock, Balance at end of period (in shares) at Jun. 30, 2022	[1]			0
Common Stock, Balance at beginning of period (in shares) at Mar. 31, 2022			32,908,922
Balance at beginning of period at Mar. 31, 2022		6,615	$ 33	$ 0	[1]	1,373	217,249	(205,112)	(6,928)
Preferred Stock, Balance at beginning of period (in shares) at Mar. 31, 2022	[1]			0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(11,718)						(11,718)
Issuance of common shares (in shares)			37,647,055
Issuance of common shares		37,201	$ 38				37,163
Issuance of warrants		0				7,503	(7,503)
Issuance of common shares under employee stock purchase plan (in shares)			53,995
Issuance of common shares under employee stock purchase plan		77					77
Share-based compensation		$ 612					612
Common Stock, Balance at end of period (in shares) at Jun. 30, 2022		70,609,972	70,609,972
Balance at end of period at Jun. 30, 2022		$ 32,787	$ 71	$ 0	[1]	$ 8,876	$ 247,598	$ (216,830)	$ (6,928)
Preferred Stock, Balance at end of period (in shares) at Jun. 30, 2022	[1]			0
[1]$0.001 par value, 10,000,000 shares authorized at June 30, 2022 and December 31, 2021.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Stockholders' Equity [Abstract]
Preferred shares, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred shares, authorized (in shares)	10,000,000	10,000,000

Consolidated Condensed Statemen

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (11,718)	$ (10,464)	$ (24,740)	$ (19,916)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant, and equipment	300	300	573	586
Amortization of intangible and leased assets			679	480
Bad debt and other non-cash receivables adjustments			59	21
Term loan discount amortization and interest accretion on debt			141	4
Share-based compensation expense	612	323	1,176	583
PPP loan forgiveness gain			0	(161)
Changes in operating assets and liabilities:
Accounts receivable			(946)	441
Inventory			(2,380)	(893)
Prepaid expenses and other current assets			(1,185)	495
Accounts payable, accrued expenses and other liabilities			1,180	2,123
Deferred revenue			8	53
Operating lease liability due to cash payments			(279)	(332)
Net cash used in operating activities			(25,714)	(16,516)
Cash flows from investing activities:
Purchase of property, plant and equipment			(634)	(411)
Payment of security deposits			(5)	(11)
Purchase of intangible assets			(1,087)	(991)
Net cash used in investing activities			(1,726)	(1,413)
Cash flows from financing activities:
Issuance of common shares			37,201	0
Issuance of common shares upon exercise of options and warrants			0	365
Issuance of common shares upon exercise of employee stock purchase plan			77	0
Proceeds from debt			0	10,000
Payment of debt issuance costs			0	(604)
Repayment of debt			0	(1,000)
Payments on finance lease obligations			(49)	(31)
Net cash provided by financing activities			37,229	8,730
Net increase (decrease) in cash, cash equivalents and restricted cash			9,789	(9,199)
Cash, cash equivalents and restricted cash at beginning of period			20,089	57,996	$ 57,996
Cash, cash equivalents and restricted cash at end of period	$ 29,878	$ 48,797	29,878	48,797	$ 20,089
Supplemental cash flow information:
Cash paid for interest			376	0
Supplemental noncash investing and financing activities:
Inventory transferred to property, plant and equipment			676	539
Property, plant and equipment transferred to intangible assets			0	46
Purchase of property, plant and equipment in accounts payable			62	189
Purchase of intangible assets in accounts payable			0	294
Fair value of warrant issued upon closing of private placement			7,503	0
Lease liabilities arising from obtaining right of use assets:
Operating leases			206	437
Finance leases			$ 73	$ 0

NATURE OF OPERATIONS

NATURE OF OPERATIONS	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF OPERATIONS	NATURE OF OPERATIONSMedAvail Holdings, Inc., or MedAvail, or the Company, a Delaware corporation formerly known as MYOS RENS Technology, is a pharmacy technology and services company that has developed and commercialized an innovative self-service pharmacy, mobile application, kiosk and drive-thru solution. The Company’s principal technology and product is the MedCenter, a pharmacist controlled, customer-interactive, prescription dispensing system akin to a “pharmacy in a box” or prescription-dispensing ATM. The MedCenter facilitates live pharmacist counseling via two-way audio-video communication with the ability to dispense prescription medicines under pharmacist control. The Company also operates SpotRx, or the Pharmacy, a full-service retail pharmacy utilizing the Company’s automated pharmacy technology.

GOING CONCERN

GOING CONCERN	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	GOING CONCERN Relevant accounting standards require that management make a determination as to whether or not substantial doubt exists as to the Company's ability to continue as a going concern. If substantial doubt does exist, then management should determine if there are plans in place which alleviate that doubt. Since inception through June 30, 2022, the Company continually incurred losses from operations which have been financed primarily by net cash proceeds from the sale of stock from private placements, the sale of redeemable preferred stock and debt. Net cash used in operating activities for six months ended June 30, 2022 and 2021 was $25.7 million and $16.5 million, respectively. As of June 30, 2022, the Company had $29.2 million in cash and cash equivalents and an accumulated deficit of $216.8 million. In April 2022, the Company completed a private placement, pursuant to which the Company received $40.0 million in gross proceeds, with an additional $10.0 million in gross proceeds received upon the second close that occurred on July 1, 2022, before deducting placement agent commissions and other offering expenses. Additionally, the private placement included warrants, some of which may be callable at the Company’s option beginning on each of the 12 month and 24 month anniversaries of the warrant issuance dates and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. See Note 11 for further information regarding the private placement warrants. Due to the Company’s significant and ongoing cash requirements to fund operations, management determined that there is substantial doubt as to the Company’s ability to continue as a going concern. The Company added liquidity resources in 2021 through a senior secured term loan facility with Silicon Valley Bank as described in Note 8, pursuant to which the Company borrowed $10.0 million in aggregate initial term loans. Additionally, as referenced above, the Company raised $40.0 million and $10.0 million in gross proceeds through a private placement that closed in April 2022 and July 2022, respectively. There can be no assurance that the steps management is taking will be successful. If the Company is unable to raise additional capital in sufficient amounts or on acceptable terms, the Company may have to significantly reduce operations or delay, scale back or discontinue development and expansion plans. The consolidated condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s ultimate success will largely depend on continued development and deployment of MedCenter kiosks and SpotRx pharmacy operations and the ability to raise significant additional funding.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited consolidated condensed financial statements as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information. Accordingly, the unaudited interim consolidated condensed financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The consolidated condensed balance sheet as of December 31, 2021 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements. In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or SEC on March 29, 2022, or the 2021 Form 10-K. The preparation of financial statements in accordance with US GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss accruals on service agreements, share-based compensation expense, allowance for doubtful accounts, depreciation and amortization and in-process research and development intangible assets, and impairment of long-lived assets and contingencies. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated condensed financial statements in the period they are deemed to be necessary. Risks and uncertainties relating to COVID-19 The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances including estimates of the impact of COVID-19. The extent to which COVID-19 impacts the Company’s business and financial results will depend on numerous evolving factors, including but not limited to, the severity and duration of COVID-19, the extent to which it will impact the Company's clinic customers, employees, suppliers, vendors, and business partners. The Company assessed certain accounting matters that require consideration of estimates and assumptions in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2022 and through the date of this report. The accounting matters assessed included, but were not limited to, the Company’s recoverability of, intangible and other long-lived assets including operating lease right-of-use assets. The Company’s future assessment of the magnitude and duration of COVID-19, as well as other factors, could result in material impacts to the Company’s consolidated condensed financial statements in future reporting periods. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results could differ from these estimates and any such differences may be material to the Company’s financial statements. Principles of consolidation The unaudited consolidated condensed financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include, MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated. Reclassifications During the fourth quarter of 2021, management reclassified certain operating expenses to reflect the costs attributable to pharmacy operations. Specifically, certain costs were reclassified from general and administrative expenses, to pharmacy operations expenses and selling and marketing expenses. This reclassification had no impact on the operating loss subtotal within the consolidated statements of operations and comprehensive loss. The effect of the reclassifications within the consolidated condensed statement of operations and comprehensive loss for 2021 are as follows (in thousands): Three Months Ended June 30, 2021 Current presentation As previously reported Change Pharmacy operations $ 3,085 $ 2,292 $ 793 General and administrative 5,737 6,646 (909) Selling and marketing 1,613 1,497 116 $ 10,435 $ 10,435 $ — Six Months Ended June 30, 2021 Current presentation As previously reported Change Pharmacy operations $ 5,678 $ 4,224 $ 1,454 General and administrative 11,413 13,136 (1,723) Selling and marketing 3,147 2,878 269 $ 20,238 $ 20,238 $ —

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Jun. 30, 2022
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. ASU No. 2016-13 will be effective beginning in the first quarter of the Company's fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated financial statements and related disclosures. In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820)”- Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, (“ASU 2022-03”). The amendments in this update clarify the guidance in Topic 820. ASU 2022-03 becomes effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. ASU No. 2022-03 will be effective beginning in the first quarter of the Company's fiscal year 2024. The Company has not yet completed its evaluation of the impact of this new guidance on its consolidated financial statements. Recently Adopted Accounting Standards There were no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated condensed financial statements through the reporting date.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE Basic earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings (loss) per share is computed by dividing net income or loss available to common stockholders by the weighted-average number of common shares plus the effect of dilutive potential common shares outstanding during the period. The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period from the date of issuance to the exercise date. After these warrants were exercised the related issued and outstanding common shares are included in weighted average shares outstanding: Shares Issuance Date Exercise Date 118,228 May 9, 2018 May 10, 2021 309,698 February 11, 2020 May 10, 2021 84,911 June 29, 2020 May 10, 2021 39,208 November 18, 2020 May 10, 2021 19,310 November 18, 2020 Outstanding

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Assets and liabilities measured at fair value on a recurring basis were as follows: Fair Value Hierarchy (in thousands) June 30, 2022 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 29,202 $ 29,202 $ — $ — Restricted cash 676 676 — — Total assets $ 29,878 $ 29,878 $ — $ — Fair Value Hierarchy (in thousands) December 31, 2021 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 19,689 $ 19,689 $ — $ — Restricted cash 400 400 — — Total assets $ 20,089 $ 20,089 $ — $ — The carrying amount of the Company's term loan approximates fair value based upon market interest rates available to us for debt of similar risk and maturities, a Level 2 input. Refer to Note 8, Debt, for further information.

BALANCE SHEET AND OTHER INFORMA

BALANCE SHEET AND OTHER INFORMATION	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BALANCE SHEET AND OTHER INFORMATION	BALANCE SHEET AND OTHER INFORMATION Restricted cash The Company considers cash to be restricted when withdrawal or general use is legally restricted. During the six months ended June 30, 2022, the Company recovered the $0.06 million restricted cash balance outstanding at December 31, 2021, that was held as a guarantee for certain purchasing cards. During the same period, pursuant to a Loan and Security Agreement with Silicon Valley Bank (see Note 8), the Company issued letters of credit to secure certain operating leases, and the Company is required to maintain a $0.68 million balance with the bank to secure the outstanding letters of credit. Due to the nature of the deposit, the balance is classified as restricted cash. Restricted cash is included in the balance for cash presented in the statements of cash flows. Inventory The following table presents detail of inventory balances: June 30, December 31, (in thousands) 2022 2021 Inventory: MedCenter hardware $ 2,132 $ 1,201 Pharmaceuticals 2,896 2,150 Spare parts 592 565 Total inventory $ 5,620 $ 3,916 Pharmaceutical inventory was recognized in pharmacy and hardware cost of products sold at $9.2 million and $4.1 million during the three months ended June 30, 2022 and 2021, respectively, and $17.1 million and $7.2 million during the six months ended June 30, 2022 and 2021, respectively. MedCenter hardware was recognized in pharmacy and hardware cost of products sold at $0.18 million and $0.20 million during the three months ended June 30, 2022 and 2021, respectively, and $0.23 million and $0.35 million during the six months ended June 30, 2022 and 2021, respectively. Prepaid expenses and other current assets The following table presents prepaid expenses and other current assets balances: June 30, December 31, (in thousands) 2022 2021 Prepaid expenses and other current assets: Prepaid MedCenter inventory $ 2,300 $ 1,050 Prepaid insurance 565 509 Other 511 632 Total prepaid expenses and other current assets $ 3,376 $ 2,191 Property, plant and equipment, net The following table presents property, plant and equipment balances: Estimated useful lives June 30, December 31, (in thousands) 2022 2021 Property, plant and equipment: MedCenter equipment 8 years $ 7,076 $ 5,875 IT equipment 1 - 3 years 2,390 2,361 Leasehold improvements lesser of useful life or term of lease 910 880 General plant and equipment 5 - 8 years 614 603 Office furniture and equipment 5 - 8 years 534 394 Vehicles 5 years 54 54 Construction-in-process 742 1,021 Total historical cost 12,320 11,188 Accumulated depreciation (5,954) (5,496) Total property, plant and equipment, net $ 6,366 $ 5,692 Depreciation expense of property and equipment was $0.3 million and $0.3 million for the three months ended June 30, 2022 and 2021, respectively, and $0.6 million and $0.6 million for the six months ended June 30, 2022 and 2021, respectively. Depreciation expense included in pharmacy and hardware cost of products sold was $0.03 million and $0.04 million for the three months ended June 30, 2022 and 2021, respectively, and $0.05 million and $0.09 million for the six months ended June 30, 2022, and 2021, respectively. Intangible assets, net The following table presents intangible asset balances: June 30, December 31, (in thousands) 2022 2021 Gross intangible assets: Intellectual property $ 3,857 $ 3,857 Software 5,321 4,475 Website and mobile application 583 583 Total intangible assets 9,761 8,915 Accumulated amortization: Intellectual property (3,857) (3,857) Software (2,470) (2,175) Website and mobile application (583) (583) Total accumulated amortization (6,910) (6,615) Total intangible assets, net $ 2,851 $ 2,300 The Company purchased $0.26 million and $0.84 million of intangible assets for the three month months ended June 30, 2022 and 2021, respectively, and $0.85 million and $1.26 million for the six months ended June 30, 2022 and 2021, respectively. Amortization expense of intangible assets was $0.17 million and $0.07 million for the three months ended June 30, 2022 and 2021, respectively, and $0.30 million and $0.10 million for the six months ended June 30, 2022 and 2021, respectively, and are included in operating expenses. The Company’s management team is evaluating its existing systems and software. If management were to determine that certain systems or software were to be replaced in order to achieve greater efficiencies, cost savings, or both, the estimated remaining useful life of some IT equipment and intangible assets may be reduced, resulting in higher depreciation and amortization expense, respectively. Lessee leases Balance sheet amounts for lease assets and leases liabilities are as follows: June 30, December 31, (in thousands) 2022 2021 Assets: Operating $ 2,247 $ 2,376 Finance 186 162 Total assets $ 2,433 $ 2,538 Liabilities: Operating: Current $ 637 $ 599 Long-term 1,836 1,947 Finance: Current 106 83 Long-term 81 80 Total liabilities $ 2,660 $ 2,709 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: June 30, December 31, (in thousands) 2022 2021 Operating leases: Weighted-average remaining lease term (years) 4.0 4.2 Weighted-average discount rate 6.9 % 6.9 % Finance leases: Weighted-average remaining lease term (years) 2.0 1.5 Weighted-average discount rate 8.4 % 8.8 % Maturities of operating leases liabilities are as follows, in thousands: Remaining period in 2022 $ 414 2023 764 2024 617 2025 534 2026 468 2027 64 Thereafter — Total lease payments 2,861 Less: present value discount (388) Total leases $ 2,473 Maturities of finance lease liabilities are as follows, in thousands: Remaining period in 2022 $ 63 2023 92 2024 47 2025 4 2026 — 2027 — Thereafter — Total finance lease payments 206 Less: imputed interest (19) Total leases $ 187 Operating lease expense was $0.2 million and $0.2 million for the three months ended June 30, 2022 and 2021, respectively, and $0.5 million and $0.4 million for the six months ended June 30, 2022 and 2021, respectively.

DEBT

DEBT	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
DEBT	DEBT The following table presents debt balances: June 30, December 31, (in thousands) 2022 2021 Term loan 10,131 10,070 Term loan issuance costs, net (452) (532) Total long-term debt, net $ 9,679 $ 9,538 Term loan

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company incurred $24,270 and $0 of income tax expense for the six months ended June 30, 2022, and 2021, respectively. The income taxes for the period ended June 30, 2022, are primarily attributed to certain federal and state taxes. The Company continues to be in a loss position as of June 30, 2022. The effective income tax rate in each period differed from the federal statutory tax rate of 21% primarily as a result of the ongoing losses. As of June 30, 2022, the Company recorded a full valuation allowance against all of its net deferred tax assets due to the uncertainty surrounding the Company’s ability to utilize these assets in the future.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Legal Following MYOS Rens Technology Inc.’s, or MYOS’s and MedAvail, Inc.’s, or MAI's, announcement of the execution of the Merger Agreement on June 30, 2020, MYOS received separate litigation demands from purported MYOS stockholders on September 16, 2020 and October 20, 2020, respectively seeking certain additional disclosures in the Form S-4 Registration Statement filed with the Securities and Exchange Commission on September 2, 2020, collectively, the Demands. Thereafter, on September 23, 2020, a complaint regarding the transactions contemplated within the Merger Agreement was filed in the Supreme Court of the State of New York, County of New York, captioned Faasse v. MYOS RENS Technology Inc., et. al., Index No.: 654644/2020 (NY Supreme Ct., NY Cnty., September 23, 2020), or the New York Complaint. On October 12, 2020, a second complaint regarding the transactions was filed in the District Court of Nevada, Clark County Nevada, captioned Vigil v. Mannello, et. al., Case No. A-20-822848-C, or the Nevada Complaint, and together with the New York Complaint, the Complaints, and collectively with the Demands, the Litigation. The Demands and the Complaints that comprised the Litigation generally alleged that the directors of MYOS breached their fiduciary duties by entering into the Merger Agreement, and MYOS and MAI disseminated an incomplete and misleading Form S-4 Registration Statement. The New York Complaint also alleged MedAvail aided and abetted such breach of fiduciary duties.

EQUITY, SHARE-BASED COMPENSATIO

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
EQUITY, SHARE-BASED COMPENSATION AND WARRANTS	EQUITY, SHARE-BASED COMPENSATION AND WARRANTS On June 14, 2022, the Company’s stockholders approved an Amended and Restated Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock, par value $0.001, from 100 million shares to a new total of 300 million shares. The Restated Certificate was effective upon filing the Restated Certificate with the Secretary of State of the State of Delaware on June 15, 2022. Private Placement On March 30, 2022, the Company entered into a Securities Purchase Agreement, or Purchase Agreement, with certain purchasers thereto, or the Investors. Pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Investors in a private placement, or the Private Placement, up to 47.1 million shares, or the Shares, of the Company’s Common Stock, and to issue warrants, or the Warrants, to purchase up to 23.5 million shares of Common Stock, or Warrant Shares. The Shares and the Warrants were sold at two closings as further described below, at a price per share of $1.0625. Each Investor purchasing Shares in the Private Placement was issued a Warrant to purchase that number of Warrant Shares equal to 50% of the number of Shares purchased under the Purchase Agreement by such Investor. The Warrants have a per share exercise price of $1.25 and will be exercisable by the holder at any time on or after the issuance date of the Warrant for a period of five years. If the Warrants were exercised in full immediately after issuance by the Investors, the Company would receive additional gross proceeds of up to $29.4 million. In addition, the Warrant terms provide the Company with a call option to force the Warrant holders to exercise up to two-thirds of the warrant shares subject to each Warrant, with one-third of the Warrant Shares being callable beginning on each of the 12 month and 24 month anniversaries of the Warrant issuance dates, in each case until the expiration of the Warrants, and subject to the satisfaction of certain pricing conditions relating to the trading of the Company’s shares. If the Company were to exercise the contingent call options immediately after issuance, approximately $19.6 million in gross proceeds could be raised. On April 4, 2022, the first closing of the Private Placement occurred, in which 37.6 million shares of Common Stock for $40.0 million in gross proceeds, before deducting placement agent commissions and other offering expenses, and Warrants exercisable for up to 18.8 million Warrant Shares were issued by the Company. A second and final closing occurred on July 1, 2022, and the Investors purchased an additional 9.4 million shares of Common Stock for $10.0 million in additional gross proceeds and Warrants exercisable for up to 4.7 million Warrants Shares. Share-based compensation The following table presents the Company's expense related to share-based compensation (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Share-based compensation $ 612 $ 323 $ 1,176 $ 583 The share-based compensation expense for the three and six months ended June 30, 2022, included $0.03 million and $0.06 million, respectively, from ESPP expense. Expense remaining to be recognized for unvested option awards from the 2012, 2018, and 2020 plans and the 2022 inducement plan as of June 30, 2022 was $2.8 million, which will be recognized on a weighted average basis over the next 2.8 years. Expense remaining to be recognized for unvested RSU awards was $2.7 million will be recognized on a weighted average basis over the next 2.5 years. The following table presents the Company's outstanding option awards activity during the six months ended June 30, 2022: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 2,848,903 $ 2.78 $ 1.44 $ 47 Granted 2,758,040 1.35 0.98 — Exercised/Released — — — — Expired (117,730) 2.08 1.13 — Forfeited (789,211) 2.41 1.36 110 Outstanding, end of period 4,700,002 $ 2.01 $ 1.19 8.60 $ 674 Vested and exercisable, end of the period 1,801,812 2.40 1.22 7.07 187 Vested and unvested exercisable, end of the period 1,801,812 2.40 1.22 7.07 187 Vested and expected to vest, end of the period 4,440,662 2.02 1.19 8.54 628 The following table presents the Company's outstanding RSU awards activity during the six months ended June 30, 2022: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 802,535 $ — $ 2.78 $ 1,124 Granted 1,601,824 — 1.41 2,252 Exercised/Released (12,048) — $ 1.90 15.15 13 Expired — — — — Forfeited (388,939) — 2.10 567 Outstanding, end of period 2,003,372 $ — $ 1.74 5.00 $ 3,065 Vested and exercisable, end of the period — — — — Vested and unvested exercisable, end of the period — — — — Vested and expected to vest, end of the period 1,817,731 — 1.75 4.99 2,781 As of June 30, 2022 and December 31, 2021, there was an aggregate of 2.4 million and 3.4 million shares of common stock, respectively, available for grant under the 2020 Plan. In April 2022, the Company adopted the MedAvail Holdings, Inc. 2022 Inducement Equity Incentive Plan or the Inducement Plan. The Inducement Plan reserved 1,500,000 shares of the Company’s common stock for issuance pursuant to equity awards granted under the Inducement Plan. On April 8, 2022, the Company issued inducement awards to employees that included options to purchase 426,500 shares of Company common stock, and 426,500 RSUs. The inducement stock options have an exercise price of $1.96, and 25% of the shares vest on the one year anniversary of the date that employment commenced, and an additional one forty-eighth (1/48th) of the shares vest monthly thereafter. The inducement RSUs vest at one-third (1/3rd) of the shares on the first, second and third yearly anniversaries of March 1, 2022. Warrants During the six months ended June 30, 2022, 18.8 million warrants were issued from the first closing of the Private Placement with a fair value of $7.5 million. No warrants were exercised during the six months ended June 30, 2022. There were 19.4 million related party warrants outstanding as of June 30, 2022. The terms for the warrants issued from the first closing of the Private Placement in April 2022 were as follows: June 30, 2022 Issue Date Reason for issuance Term (years) Exercise Price (USD) April 4, 2022 Private Placement 5 $ 1.25

REVENUE AND SEGMENT REPORTING

REVENUE AND SEGMENT REPORTING	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
REVENUE AND SEGMENT REPORTING	REVENUE AND SEGMENT REPORTING Operating segments are the individual operations that the chief operating decision maker, or CODM, who is the Company's chief executive officer, reviews for purposes of assessing performance and making resource allocation decisions. The CODM currently receives the monthly management report which includes information to assess performance. The retail pharmacy services and pharmacy technology operating segments both engage in different business activities from which they earn revenues and incur expenses. The Company has the following two reportable segments: Retail Pharmacy Services Segment Retail Pharmacy Services segment revenue consists of products sold directly to consumers at the point of sale. MedAvail recognizes retail pharmacy revenue, net of taxes and expected returns, at the time it sells merchandise or dispenses prescription drugs to the customer. The Company estimates revenue based on expected reimbursements from third-party payers (e.g., pharmacy benefit managers, insurance companies and governmental agencies) for dispensing prescription drugs. The estimates are based on all available information including historical experience and are updated to actual reimbursement amounts. Pharmacy Technology Segment The Pharmacy Technology Segment consists of sales and subscriptions of MedPlatform systems to customers. These agreements include providing the MedCenter prescription dispensing kiosk, software, and maintenance services. This generally includes either an initial lump sum payment upon installation of the MedCenter with monthly payments for software and services following, or monthly payments for the MedCenter along with monthly payments for software and maintenance services for subscription agreements. The following table presents revenue and costs of products sold and services by segment (in thousands): Retail Pharmacy Services Pharmacy Technology Total Three Months Ended June 30, 2022 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 10,641 $ — $ 10,641 Hardware — 180 180 Subscription — 109 109 Total pharmacy and hardware revenue 10,641 289 10,930 Service revenue: Software — 86 86 Maintenance and support — 47 47 Installation — 71 71 Professional services and other — 50 50 Total service revenue — 254 254 Total revenue 10,641 543 11,184 Cost of products sold and services 9,930 336 10,266 Segment gross profit $ 711 $ 207 918 Operating Expense: Pharmacy operations 3,648 General and administrative 6,100 Selling and marketing 2,307 Research and development 281 Total operating expense 12,336 Operating loss $ (11,418) Retail Pharmacy Services Pharmacy Technology Total Three Months Ended June 30, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 4,494 $ — $ 4,494 Hardware — 123 123 Subscription — 108 108 Total pharmacy and hardware revenue 4,494 231 4,725 Service revenue: Software — 41 41 Maintenance and support — 40 40 Installation — 12 12 Professional services and other — 212 212 Total service revenue — 305 305 Total revenue 4,494 536 5,030 Cost of products sold and services 4,435 422 4,857 Segment gross profit $ 59 $ 114 173 Operating Expense: Pharmacy operations 3,085 General and administrative 5,737 Selling and marketing 1,613 Research and development 201 Total operating expense 10,636 Operating loss $ (10,463) Retail Pharmacy Services Pharmacy Technology Total Six Months Ended June 30, 2022 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 19,490 $ — $ 19,490 Hardware — 236 236 Subscription — 218 218 Total pharmacy and hardware revenue 19,490 454 19,944 Service revenue: Software — 133 133 Maintenance and support — 79 79 Installation — 77 77 Professional services and other — 65 65 Total service revenue — 354 354 Total revenue 19,490 808 20,298 Cost of products sold and services 18,412 467 18,879 Segment gross profit $ 1,078 $ 341 1,419 Operating Expense: Pharmacy operations 7,578 General and administrative 12,642 Selling and marketing 4,612 Research and development 774 Total operating expense 25,606 Operating loss $ (24,187) Retail Pharmacy Services Pharmacy Technology Total Six Months Ended June 30, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 7,912 $ — $ 7,912 Hardware — 364 364 Subscription — 230 230 Total pharmacy and hardware revenue 7,912 594 8,506 Service revenue: Software — 74 74 Maintenance and support — 71 71 Installation — 28 28 Professional services and other — 378 378 Total service revenue — 551 551 Total revenue 7,912 1,145 9,057 Cost of products sold and services 7,764 800 8,564 Segment gross profit $ 148 $ 345 493 Operating Expense: Pharmacy operations 5,678 General and administrative 11,413 Selling and marketing 3,147 Research and development 369 Total operating expense 20,607 Operating loss $ (20,114) The following table presents assets and liabilities by segment (in thousands): Retail Pharmacy Services Pharmacy Technology Corporate Total June 30, 2022 Assets $ 16,253 $ 8,335 $ 28,245 $ 52,833 Liabilities $ 6,462 $ 3,404 $ 10,180 $ 20,046 December 31, 2021 Assets $ 13,641 $ 5,222 $ 19,280 $ 38,143 Liabilities $ 5,618 $ 3,567 $ 9,885 $ 19,070 The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets (in thousands): June 30, December 31, 2022 2021 Long-lived assets: United States $ 8,365 $ 7,675 Canada 434 555 Total long-lived assets $ 8,799 $ 8,230

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited consolidated condensed financial statements as of June 30, 2022 and for the three and six months ended June 30, 2022 and 2021 have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") for unaudited interim financial information. Accordingly, the unaudited interim consolidated condensed financial statements do not include all of the information and footnotes required by GAAP for audited financial statements. The consolidated condensed balance sheet as of December 31, 2021 was derived from the Company's audited consolidated financial statements but does not include all disclosures required by GAAP for audited financial statements. In the opinion of the Company's management, the interim information includes all adjustments, which include normal recurring adjustments, necessary for a fair statement of the results for the interim periods. The footnote disclosures related to the interim financial information included herein are also unaudited. Such financial information should be read in conjunction with the consolidated financial statements and related notes thereto for the year ended December 31, 2021 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or SEC on March 29, 2022, or the 2021 Form 10-K. The preparation of financial statements in accordance with US GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. Actual results could differ from those estimates. Estimates are used in accounting for, among other things, revenue recognition, contract loss accruals, excess, slow-moving and obsolete inventories, product warranty accruals, loss
Principles of consolidation	Principles of consolidation The unaudited consolidated condensed financial statements include the accounts of all entities controlled by MedAvail Holdings, Inc., which are referred to as subsidiaries. The Company's subsidiaries include, MedAvail Technologies, Inc., MedAvail Technologies (US), Inc., MedAvail Pharmacy, Inc., and MedAvail, Inc. The Company has no interests in variable interest entities of which the Company is the primary beneficiary. All intercompany balances and transactions have been eliminated.
Recent Accounting Pronouncements and Recently Adopted Accounting Standards	Measurement of Credit Losses on Financial Statements In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments-Credit Losses (Topic 326)”- Measurement of Credit Losses on Financial Instruments”, (“ASU 2016-13”), supplemented by ASU 2018-19, “Codification Improvements to Topic 326, Financial Instruments – Credit Losses”, (“ASU 2018-19”). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 became effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2019, other than smaller reporting companies, all other public business entities and private companies, with early adoption permitted. ASU No. 2016-13 will be effective beginning in the first quarter of the Company's fiscal year 2023. The Company is currently evaluating the impact that this new guidance will have on its consolidated financial statements and related disclosures. In June 2022, the FASB issued ASU No. 2022-03, “Fair Value Measurement (Topic 820)”- Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”, (“ASU 2022-03”). The amendments in this update clarify the guidance in Topic 820. ASU 2022-03 becomes effective for Public Business Entities who are SEC filers for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted. ASU No. 2022-03 will be effective beginning in the first quarter of the Company's fiscal year 2024. The Company has not yet completed its evaluation of the impact of this new guidance on its consolidated financial statements. Recently Adopted Accounting Standards There were no recently issued and effective authoritative guidance that is expected to have a material impact on the Company’s consolidated condensed financial statements through the reporting date.

BASIS OF PRESENTATION (Tables)

BASIS OF PRESENTATION (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Error Corrections and Prior Period Adjustments	The effect of the reclassifications within the consolidated condensed statement of operations and comprehensive loss for 2021 are as follows (in thousands): Three Months Ended June 30, 2021 Current presentation As previously reported Change Pharmacy operations $ 3,085 $ 2,292 $ 793 General and administrative 5,737 6,646 (909) Selling and marketing 1,613 1,497 116 $ 10,435 $ 10,435 $ — Six Months Ended June 30, 2021 Current presentation As previously reported Change Pharmacy operations $ 5,678 $ 4,224 $ 1,454 General and administrative 11,413 13,136 (1,723) Selling and marketing 3,147 2,878 269 $ 20,238 $ 20,238 $ —

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Warrants Included in Earnings per Share	The following table presents warrants included in weighted average shares outstanding due to their insignificant exercise price, during the period from the date of issuance to the exercise date. After these warrants were exercised the related issued and outstanding common shares are included in weighted average shares outstanding: Shares Issuance Date Exercise Date 118,228 May 9, 2018 May 10, 2021 309,698 February 11, 2020 May 10, 2021 84,911 June 29, 2020 May 10, 2021 39,208 November 18, 2020 May 10, 2021 19,310 November 18, 2020 Outstanding

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis were as follows: Fair Value Hierarchy (in thousands) June 30, 2022 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 29,202 $ 29,202 $ — $ — Restricted cash 676 676 — — Total assets $ 29,878 $ 29,878 $ — $ — Fair Value Hierarchy (in thousands) December 31, 2021 Level 1 Level 2 Level 3 Assets: Cash and cash equivalents $ 19,689 $ 19,689 $ — $ — Restricted cash 400 400 — — Total assets $ 20,089 $ 20,089 $ — $ —

BALANCE SHEET AND OTHER INFOR_2

BALANCE SHEET AND OTHER INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Inventory	The following table presents detail of inventory balances: June 30, December 31, (in thousands) 2022 2021 Inventory: MedCenter hardware $ 2,132 $ 1,201 Pharmaceuticals 2,896 2,150 Spare parts 592 565 Total inventory $ 5,620 $ 3,916
Schedule of Prepaid Expenses and Other Current Assets	The following table presents prepaid expenses and other current assets balances: June 30, December 31, (in thousands) 2022 2021 Prepaid expenses and other current assets: Prepaid MedCenter inventory $ 2,300 $ 1,050 Prepaid insurance 565 509 Other 511 632 Total prepaid expenses and other current assets $ 3,376 $ 2,191
Schedule of Property, Plant and Equipment, Net and Useful Lives	The following table presents property, plant and equipment balances: Estimated useful lives June 30, December 31, (in thousands) 2022 2021 Property, plant and equipment: MedCenter equipment 8 years $ 7,076 $ 5,875 IT equipment 1 - 3 years 2,390 2,361 Leasehold improvements lesser of useful life or term of lease 910 880 General plant and equipment 5 - 8 years 614 603 Office furniture and equipment 5 - 8 years 534 394 Vehicles 5 years 54 54 Construction-in-process 742 1,021 Total historical cost 12,320 11,188 Accumulated depreciation (5,954) (5,496) Total property, plant and equipment, net $ 6,366 $ 5,692
Schedule of Finite-Lived Intangible Assets, Net	The following table presents intangible asset balances: June 30, December 31, (in thousands) 2022 2021 Gross intangible assets: Intellectual property $ 3,857 $ 3,857 Software 5,321 4,475 Website and mobile application 583 583 Total intangible assets 9,761 8,915 Accumulated amortization: Intellectual property (3,857) (3,857) Software (2,470) (2,175) Website and mobile application (583) (583) Total accumulated amortization (6,910) (6,615) Total intangible assets, net $ 2,851 $ 2,300
Schedule of Lease Assets and Liabilities	Balance sheet amounts for lease assets and leases liabilities are as follows: June 30, December 31, (in thousands) 2022 2021 Assets: Operating $ 2,247 $ 2,376 Finance 186 162 Total assets $ 2,433 $ 2,538 Liabilities: Operating: Current $ 637 $ 599 Long-term 1,836 1,947 Finance: Current 106 83 Long-term 81 80 Total liabilities $ 2,660 $ 2,709 The following table summarizes the weighted-average remaining lease term and weighted-average discount rate related to the Company’s leases as follows: June 30, December 31, (in thousands) 2022 2021 Operating leases: Weighted-average remaining lease term (years) 4.0 4.2 Weighted-average discount rate 6.9 % 6.9 % Finance leases: Weighted-average remaining lease term (years) 2.0 1.5 Weighted-average discount rate 8.4 % 8.8 %
Schedule of Maturities of Operating Lease Liabilities	Maturities of operating leases liabilities are as follows, in thousands: Remaining period in 2022 $ 414 2023 764 2024 617 2025 534 2026 468 2027 64 Thereafter — Total lease payments 2,861 Less: present value discount (388) Total leases $ 2,473
Schedule of Maturities of Finance Lease Liabilities	Maturities of finance lease liabilities are as follows, in thousands: Remaining period in 2022 $ 63 2023 92 2024 47 2025 4 2026 — 2027 — Thereafter — Total finance lease payments 206 Less: imputed interest (19) Total leases $ 187

DEBT (Tables)

DEBT (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Debt	The following table presents debt balances: June 30, December 31, (in thousands) 2022 2021 Term loan 10,131 10,070 Term loan issuance costs, net (452) (532) Total long-term debt, net $ 9,679 $ 9,538

EQUITY, SHARE-BASED COMPENSAT_2

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of MedAvail Share-based Compensation Expense	The following table presents the Company's expense related to share-based compensation (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Share-based compensation $ 612 $ 323 $ 1,176 $ 583
Schedule of Outstanding Option Awards Activity	The following table presents the Company's outstanding option awards activity during the six months ended June 30, 2022: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 2,848,903 $ 2.78 $ 1.44 $ 47 Granted 2,758,040 1.35 0.98 — Exercised/Released — — — — Expired (117,730) 2.08 1.13 — Forfeited (789,211) 2.41 1.36 110 Outstanding, end of period 4,700,002 $ 2.01 $ 1.19 8.60 $ 674 Vested and exercisable, end of the period 1,801,812 2.40 1.22 7.07 187 Vested and unvested exercisable, end of the period 1,801,812 2.40 1.22 7.07 187 Vested and expected to vest, end of the period 4,440,662 2.02 1.19 8.54 628
Schedule of Outstanding RSU Awards Activity	The following table presents the Company's outstanding RSU awards activity during the six months ended June 30, 2022: (in thousands, except for share and per share amounts) Number of Awards Weighted Average Exercise Price Weighted Average Share Price on Date of Exercise Weighted Average Fair Value Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding, beginning of period 802,535 $ — $ 2.78 $ 1,124 Granted 1,601,824 — 1.41 2,252 Exercised/Released (12,048) — $ 1.90 15.15 13 Expired — — — — Forfeited (388,939) — 2.10 567 Outstanding, end of period 2,003,372 $ — $ 1.74 5.00 $ 3,065 Vested and exercisable, end of the period — — — — Vested and unvested exercisable, end of the period — — — — Vested and expected to vest, end of the period 1,817,731 — 1.75 4.99 2,781
Schedule of Warrants Issued	The terms for the warrants issued from the first closing of the Private Placement in April 2022 were as follows: June 30, 2022 Issue Date Reason for issuance Term (years) Exercise Price (USD) April 4, 2022 Private Placement 5 $ 1.25

REVENUE AND SEGMENT REPORTING (

REVENUE AND SEGMENT REPORTING (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Schedule of Revenue and Costs of Sales by Segment	The following table presents revenue and costs of products sold and services by segment (in thousands): Retail Pharmacy Services Pharmacy Technology Total Three Months Ended June 30, 2022 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 10,641 $ — $ 10,641 Hardware — 180 180 Subscription — 109 109 Total pharmacy and hardware revenue 10,641 289 10,930 Service revenue: Software — 86 86 Maintenance and support — 47 47 Installation — 71 71 Professional services and other — 50 50 Total service revenue — 254 254 Total revenue 10,641 543 11,184 Cost of products sold and services 9,930 336 10,266 Segment gross profit $ 711 $ 207 918 Operating Expense: Pharmacy operations 3,648 General and administrative 6,100 Selling and marketing 2,307 Research and development 281 Total operating expense 12,336 Operating loss $ (11,418) Retail Pharmacy Services Pharmacy Technology Total Three Months Ended June 30, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 4,494 $ — $ 4,494 Hardware — 123 123 Subscription — 108 108 Total pharmacy and hardware revenue 4,494 231 4,725 Service revenue: Software — 41 41 Maintenance and support — 40 40 Installation — 12 12 Professional services and other — 212 212 Total service revenue — 305 305 Total revenue 4,494 536 5,030 Cost of products sold and services 4,435 422 4,857 Segment gross profit $ 59 $ 114 173 Operating Expense: Pharmacy operations 3,085 General and administrative 5,737 Selling and marketing 1,613 Research and development 201 Total operating expense 10,636 Operating loss $ (10,463) Retail Pharmacy Services Pharmacy Technology Total Six Months Ended June 30, 2022 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 19,490 $ — $ 19,490 Hardware — 236 236 Subscription — 218 218 Total pharmacy and hardware revenue 19,490 454 19,944 Service revenue: Software — 133 133 Maintenance and support — 79 79 Installation — 77 77 Professional services and other — 65 65 Total service revenue — 354 354 Total revenue 19,490 808 20,298 Cost of products sold and services 18,412 467 18,879 Segment gross profit $ 1,078 $ 341 1,419 Operating Expense: Pharmacy operations 7,578 General and administrative 12,642 Selling and marketing 4,612 Research and development 774 Total operating expense 25,606 Operating loss $ (24,187) Retail Pharmacy Services Pharmacy Technology Total Six Months Ended June 30, 2021 Revenue: Pharmacy and hardware revenue: Retail pharmacy revenue $ 7,912 $ — $ 7,912 Hardware — 364 364 Subscription — 230 230 Total pharmacy and hardware revenue 7,912 594 8,506 Service revenue: Software — 74 74 Maintenance and support — 71 71 Installation — 28 28 Professional services and other — 378 378 Total service revenue — 551 551 Total revenue 7,912 1,145 9,057 Cost of products sold and services 7,764 800 8,564 Segment gross profit $ 148 $ 345 493 Operating Expense: Pharmacy operations 5,678 General and administrative 11,413 Selling and marketing 3,147 Research and development 369 Total operating expense 20,607 Operating loss $ (20,114)
Schedule of Assets and Liabilities by Segment	The following table presents assets and liabilities by segment (in thousands): Retail Pharmacy Services Pharmacy Technology Corporate Total June 30, 2022 Assets $ 16,253 $ 8,335 $ 28,245 $ 52,833 Liabilities $ 6,462 $ 3,404 $ 10,180 $ 20,046 December 31, 2021 Assets $ 13,641 $ 5,222 $ 19,280 $ 38,143 Liabilities $ 5,618 $ 3,567 $ 9,885 $ 19,070 The following table presents long-lived assets, which include property, plant, and equipment and right-of-use-assets by geographic region, based on the physical location of the assets (in thousands): June 30, December 31, 2022 2021 Long-lived assets: United States $ 8,365 $ 7,675 Canada 434 555 Total long-lived assets $ 8,799 $ 8,230

GOING CONCERN (Details)

GOING CONCERN (Details) - USD ($) $ in Thousands			1 Months Ended		6 Months Ended		12 Months Ended
	Jul. 01, 2022	Apr. 04, 2022	Jul. 31, 2022	Apr. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Debt Instrument [Line Items]
Operating cash flows					$ (25,714)	$ (16,516)
Cash and cash equivalents					29,202		$ 19,689
Accumulated deficit					216,830		192,090
Proceeds from debt					$ 0	$ 10,000
Term loan | Secured Debt
Debt Instrument [Line Items]
Proceeds from debt							$ 10,000
Minimum
Debt Instrument [Line Items]
Warrants, callable term				12 months
Maximum
Debt Instrument [Line Items]
Warrants, callable term				24 months
Private Placement
Debt Instrument [Line Items]
Gross proceeds from private placement		$ 40,000		$ 40,000
Private Placement | Subsequent Event
Debt Instrument [Line Items]
Gross proceeds from private placement	$ 10,000		$ 10,000

BASIS OF PRESENTATION - Reclass

BASIS OF PRESENTATION - Reclassifications (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Pharmacy operations	$ 3,648	$ 3,085	$ 7,578	$ 5,678
General and administrative	6,100	5,737	12,642	11,413
Selling and marketing	$ 2,307	1,613	$ 4,612	3,147
Total		10,435		20,238
As previously reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Pharmacy operations		2,292		4,224
General and administrative		6,646		13,136
Selling and marketing		1,497		2,878
Total		10,435		20,238
Change
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Pharmacy operations		793		1,454
General and administrative		(909)		(1,723)
Selling and marketing		116		269
Total		$ 0		$ 0

EARNINGS (LOSS) PER SHARE - War

EARNINGS (LOSS) PER SHARE - Warrants Included in Earnings per Share (Details)	6 Months Ended
	Jun. 30, 2022 shares
Warrants Issued May 9, 2018
Class of Warrant or Right [Line Items]
Warrants (in shares)	118,228
Warrants Issued February 11, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)	309,698
Warrants Issued June 29, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)	84,911
Warrants Issued November 18, 2020
Class of Warrant or Right [Line Items]
Warrants (in shares)	39,208
Warrants Issued November 18, 2020, Outstanding
Class of Warrant or Right [Line Items]
Warrants (in shares)	19,310

EARNINGS (LOSS) PER SHARE - Nar

EARNINGS (LOSS) PER SHARE - Narrative (Details) - shares shares in Millions	6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive option awards excluded from earnings per share calculation (in shares)	4.7	2.1
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive option awards excluded from earnings per share calculation (in shares)	19.6		0.7

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 29,202	$ 19,689
Restricted cash	676	400
Total assets	29,878	20,089
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	29,202	19,689
Restricted cash	676	400
Total assets	29,878	20,089
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Total assets	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Restricted cash	0	0
Total assets	$ 0	$ 0

BALANCE SHEET AND OTHER INFOR_3

BALANCE SHEET AND OTHER INFORMATION - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Inventory [Line Items]
Restricted cash	$ 676		$ 676		$ 400
Depreciation of property, plant, and equipment	300	$ 300	573	$ 586
Depreciation included in cost of sales	30	40	50	90
Increase of intangible assets during the period	260	840	850	1,260
Amortization of intangible assets	170	70	300	100
Operating lease, expense	200	200	500	400
Pharmacy
Inventory [Line Items]
Inventory recognized as cost of sales	9,200	4,100	17,100	7,200
MedCenter
Inventory [Line Items]
Inventory recognized as cost of sales	180	$ 200	230	$ 350
Guarantee for Purchasing Cards
Inventory [Line Items]
Cash released from restriction			60
Letter of Credit Security
Inventory [Line Items]
Restricted cash	$ 680		$ 680

BALANCE SHEET AND OTHER INFOR_4

BALANCE SHEET AND OTHER INFORMATION - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
MedCenter hardware	$ 2,132	$ 1,201
Pharmaceuticals	2,896	2,150
Spare parts	592	565
Total inventory	$ 5,620	$ 3,916

BALANCE SHEET AND OTHER INFOR_5

BALANCE SHEET AND OTHER INFORMATION - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Prepaid expenses and other current assets:
Prepaid MedCenter inventory	$ 2,300	$ 1,050
Prepaid insurance	565	509
Other	511	632
Total prepaid expenses and other current assets	$ 3,376	$ 2,191

BALANCE SHEET AND OTHER INFOR_6

BALANCE SHEET AND OTHER INFORMATION - Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Historical cost	$ 12,320	$ 11,188
Accumulated depreciation	(5,954)	(5,496)
Total property, plant and equipment, net	$ 6,366	5,692
MedCenter equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Historical cost	$ 7,076	5,875
IT equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 2,390	2,361
IT equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	1 year
IT equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Leasehold improvements
Property, Plant and Equipment [Line Items]
Historical cost	$ 910	880
General plant and equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 614	603
General plant and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
General plant and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Office furniture and equipment
Property, Plant and Equipment [Line Items]
Historical cost	$ 534	394
Office furniture and equipment | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Office furniture and equipment | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Vehicles
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Historical cost	$ 54	54
Construction-in-process
Property, Plant and Equipment [Line Items]
Historical cost	$ 742	$ 1,021

BALANCE SHEET AND OTHER INFOR_7

BALANCE SHEET AND OTHER INFORMATION - Intangible Assets, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	$ 9,761	$ 8,915
Accumulated amortization	(6,910)	(6,615)
Total intangible assets, net	2,851	2,300
Intellectual property
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	3,857	3,857
Accumulated amortization	(3,857)	(3,857)
Software
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	5,321	4,475
Accumulated amortization	(2,470)	(2,175)
Website and mobile application
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets	583	583
Accumulated amortization	$ (583)	$ (583)

BALANCE SHEET AND OTHER INFOR_8

BALANCE SHEET AND OTHER INFORMATION - Leases, Balance Sheet Information (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Assets
Operating	$ 2,247	$ 2,376
Finance	186	162
Total assets	2,433	2,538
Operating:
Current	637	599
Long-term	1,836	1,947
Finance:
Current	106	83
Long-term	81	80
Total liabilities	$ 2,660	$ 2,709

BALANCE SHEET AND OTHER INFOR_9

BALANCE SHEET AND OTHER INFORMATION - Additional Lease Information (Details)	Jun. 30, 2022	Dec. 31, 2021
Operating leases:
Weighted-average remaining lease term (years)	4 years	4 years 2 months 12 days
Weighted-average discount rate	6.90%	6.90%
Finance leases:
Weighted-average remaining lease term (years)	2 years	1 year 6 months
Weighted-average discount rate	8.40%	8.80%

BALANCE SHEET AND OTHER INFO_10

BALANCE SHEET AND OTHER INFORMATION - Leases, Operating Lease Liability Maturity (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remaining period in 2022	$ 414
2023	764
2024	617
2025	534
2026	468
2027	64
Thereafter	0
Total lease payments	2,861
Less: present value discount	(388)
Total leases	$ 2,473

BALANCE SHEET AND OTHER INFO_11

BALANCE SHEET AND OTHER INFORMATION - Leases, Finance Lease Liability Maturity (Details) $ in Thousands	Jun. 30, 2022 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remaining period in 2022	$ 63
2023	92
2024	47
2025	4
2026	0
2027	0
Thereafter	0
Total finance lease payments	206
Less: imputed interest	(19)
Total leases	$ 187

DEBT - Schedule of Debt (Detail

DEBT - Schedule of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long-term debt, net	$ 9,679	$ 9,538
Term loan | Secured Debt
Debt Instrument [Line Items]
Term loan	10,131	10,070
Term loan issuance costs, net	$ (452)	$ (532)

DEBT - Narrative (Details)

DEBT - Narrative (Details) - Term loan - Secured Debt $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($)
Debt Instrument [Line Items]
Debt instrument, interest rate floor	7.25%
Interest rate at end of period	8.75%
Additional borrowing capacity available	$ 20
Prime Rate
Debt Instrument [Line Items]
Variable interest rate spread	4%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 24,000	$ 0	$ 24,270	$ 0

EQUITY, SHARE-BASED COMPENSAT_3

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Equity, Narrative (Details) - $ / shares	Jun. 30, 2022	Jun. 14, 2022	Jun. 13, 2022	Dec. 31, 2021
Equity [Abstract]
Common shares, par value (in USD per share)	$ 0.001	$ 0.001		$ 0.001
Common shares, authorized (in shares)	300,000,000	300,000,000	100,000,000	300,000,000

EQUITY, SHARE-BASED COMPENSAT_4

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Private Placement, Narrative (Details) $ / shares in Units, shares in Millions, $ in Millions			1 Months Ended
	Jul. 01, 2022 USD ($) shares	Apr. 04, 2022 USD ($) shares	Jul. 31, 2022 USD ($)	Apr. 30, 2022 USD ($)	Jun. 30, 2022	Mar. 30, 2022 USD ($) closing $ / shares shares
Minimum
Subsidiary, Sale of Stock [Line Items]
Warrants, callable term				12 months
Maximum
Subsidiary, Sale of Stock [Line Items]
Warrants, callable term				24 months
Warrant Shares
Subsidiary, Sale of Stock [Line Items]
Exercise price of warrants issued (in USD per share) | $ / shares						$ 1.25
Term of warrants (in years)						5 years
Proceeds to be received if warrants are exercised in full | $						$ 29.4
Percentage of warrants callable						66.67%
Exercise the contingent call options, additional equity | $						$ 19.6
Warrant Shares | Warrants Callable at 12 Months
Subsidiary, Sale of Stock [Line Items]
Percentage of warrants callable						33.33%
Warrant Shares | Warrants Callable at 24 Months
Subsidiary, Sale of Stock [Line Items]
Percentage of warrants callable					33.33%
Private Placement
Subsidiary, Sale of Stock [Line Items]
Number of shares authorized to be sold (in shares)						47.1
Number of shares called by warrants (in shares)						23.5
Number of closings | closing						2
Sale of stock (in USD per share) | $ / shares						$ 1.0625
Warrants issued as a percentage of shares purchased						50%
Number of shares sold or expected to be sold (in shares)		37.6
Gross proceeds from private placement | $		$ 40		$ 40
Number of warrants issued (in shares)		18.8
Private Placement | Subsequent Event
Subsidiary, Sale of Stock [Line Items]
Number of shares sold or expected to be sold (in shares)	9.4
Gross proceeds from private placement | $	$ 10		$ 10
Number of warrants issued (in shares)	4.7

EQUITY, SHARE-BASED COMPENSAT_5

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Equity [Abstract]
Share-based compensation expense	$ 612	$ 323	$ 1,176	$ 583

EQUITY, SHARE-BASED COMPENSAT_6

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Share Based Compensation, Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	6 Months Ended
	Apr. 08, 2022	Jun. 30, 2022	Jun. 30, 2022	Apr. 30, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense remaining to be recognized		$ 2,800	$ 2,800
Weighted average recognition period (in years)			2 years 9 months 18 days
Aggregate shares on common stock available for grant (in shares)		2,400,000	2,400,000		3,400,000
Granted (in shares)	426,500		2,758,040
Exercise price (in USD per share)	$ 1.96		$ 1.35
2022 Inducement Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance (in shares)				1,500,000
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation		$ 30	$ 60
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense remaining to be recognized		$ 2,700	$ 2,700
Weighted average recognition period (in years)			2 years 6 months
Granted (in shares)	426,500
Restricted Stock Units (RSUs) | 2022 Inducement Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting rights	33.33%
Option | Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting rights	25%
Option | Share-based Payment Arrangement, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vesting rights	2.08%

EQUITY, SHARE-BASED COMPENSAT_7

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended
	Apr. 08, 2022	Jun. 30, 2022
Number of Awards
Outstanding awards at beginning of period (in shares)		2,848,903
Granted (in shares)	426,500	2,758,040
Exercised/released (in shares)		0
Expired (in shares)		(117,730)
Forfeited (in shares)		(789,211)
Outstanding awards at end of period (in shares)		4,700,002
Awards vested and exercisable (in shares)		1,801,812
Awards vested and unvested exercisable (in shares)		1,801,812
Awards vested and expected to vest (in shares)		4,440,662
Weighted Average Exercise Price
Weighted average exercise price of awards outstanding at beginning of period (in USD per share)		$ 2.78
Weighted average exercise price of awards granted (in USD per share)	$ 1.96	1.35
Weighted average exercise price of awards exercised/released (in USD per share)		0
Weighted average exercise price of awards expired (in USD per share)		2.08
Weighted average exercise price of awards forfeited (in USD per share)		2.41
Weighted average exercise price of awards outstanding at end of period (in USD per share)		2.01
Weighted average exercise price of awards vested and exercisable (in USD per share)		2.40
Weighted average exercise price of awards vested and unvested exercisable (in USD per share)		2.40
Weighted average exercise price of awards vested and expected to vest (in USD per share)		2.02
Weighted Average Fair Value
Weighted average fair value of awards outstanding at beginning of period (in USD per share)		1.44
Grant date fair value of options granted (in USD per share)		0.98
Weighted average fair value of awards exercised/released (in USD per share)		0
Weighted average fair value of awards expired (in USD per share)		1.13
Weighted average fair value of awards forfeited (in USD per share)		1.36
Weighted average fair value of awards outstanding at end of period (in USD per share)		1.19
Weighted average fair value of awards vested and exercisable (in USD per share)		1.22
Weighted average fair value of awards vested and unvested exercisable (in USD per share)		1.22
Weighted average fair value of awards vested and expected to vest (in USD per share)		$ 1.19
Weighted Average Remaining Contractual Life (Years)
Outstanding, end of period		8 years 7 months 6 days
Vested and exercisable, end of the period		7 years 25 days
Vested and unvested exercisable, end of the period		7 years 25 days
Vested and expected to vest, end of the period		8 years 6 months 14 days
Aggregate Intrinsic Value
Aggregate intrinsic value of awards outstanding at beginning of period		$ 47
Aggregate intrinsic value of awards granted		0
Aggregate intrinsic value of awards exercised/released		0
Aggregate intrinsic value of awards expired		0
Aggregate intrinsic value of awards forfeited		110
Aggregate intrinsic value of awards outstanding at end of period		674
Aggregate intrinsic value of awards vested and exercisable		187
Aggregate intrinsic value of awards vested and unvested exercisable		187
Aggregate intrinsic value of awards vested and expected to vest		$ 628

EQUITY, SHARE-BASED COMPENSAT_8

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - RSU Activity (Details) - Restricted Stock Units (RSUs) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares
Number of Awards
Outstanding awards at beginning of period (in shares) | shares	802,535
Granted (in shares) | shares	1,601,824
Exercised/Released (in shares) | shares	(12,048)
Expired (in shares) | shares	0
Forfeited (in shares) | shares	(388,939)
Outstanding awards at end of period (in shares) | shares	2,003,372
Vested and exercisable, end of the period (in shares) | shares	0
Vested and unvested exercisable, end of the period (in shares) | shares	0
Vested and expected to vest, end of the period (in shares) | shares	1,817,731
Weighted Average Share Price on Date of Exercise
Weighted average share price on date of exercise (in USD per share)	$ 1.90
Weighted Average Fair Value
Weighted average fair value of awards outstanding at beginning of period (in USD per share)	2.78
Weighted average grant date fair value of options granted (in USD per share)	1.41
Weighted average fair value of awards exercised/released (in USD per share)	15.15
Weighted average fair value of awards expired (in USD per share)	0
Weighted average fair value of awards cancelled/forfeited (in USD per share)	2.10
Weighted average fair value of awards outstanding at end of period (in USD per share)	1.74
Weighted average fair value of awards vested and exercisable (in USD per share)	0
Weighted average fair value of awards vested and unvested exercisable (in USD per share)	0
Weighted average fair value of awards vested and expected to vest (in USD per share)	$ 1.75
Weighted Average Remaining Contractual Life (Years)
Weighted average remaining contractual life	5 years
Vested and expected to vest, end of the period	4 years 11 months 26 days
Aggregate Intrinsic Value
Aggregate intrinsic value of awards outstanding at beginning of period | $	$ 1,124
Aggregate intrinsic value of awards granted | $	2,252
Aggregate intrinsic value of awards exercised/released | $	13
Aggregate intrinsic value of awards expired | $	0
Aggregate intrinsic value of awards forfeited | $	567
Aggregate intrinsic value of awards outstanding at end of period | $	3,065
Aggregate intrinsic value of awards vested and exercisable | $	0
Aggregate intrinsic value of awards vested and unvested exercisable | $	0
Aggregate intrinsic value of awards vested and expected to vest | $	$ 2,781

EQUITY, SHARE-BASED COMPENSAT_9

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Warrants, Narrative (Details) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($) shares
Class of Warrant or Right [Line Items]
Warrants issued during the period (in shares)	18,800,000
Fair value of warrants | $	$ 7.5
Exercise of warrants (in shares)	0
Investors
Class of Warrant or Right [Line Items]
Warrants (in shares)	19,400,000

EQUITY, SHARE-BASED COMPENSA_10

EQUITY, SHARE-BASED COMPENSATION AND WARRANTS - Schedule of Warrants Issued (Details) - Warrants Issued April 04, 2022, Exercise Price	Dec. 31, 2020 $ / shares
Class of Warrant or Right [Line Items]
Term of warrants (in years)	5 years
Exercise price of warrants issued (in USD per share)	$ 1.25

REVENUE AND SEGMENT REPORTING -

REVENUE AND SEGMENT REPORTING - Narrative (Details)	6 Months Ended
	Jun. 30, 2022 segment
Segment Reporting [Abstract]
Number of reportable segments	2

REVENUE AND SEGMENT REPORTING_2

REVENUE AND SEGMENT REPORTING - Schedule of Revenue and Cost of Sales (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	$ 11,184	$ 5,030	$ 20,298	$ 9,057
Total cost of products sold and services	10,266	4,857	18,879	8,564
Operating expense:	918	173	1,419	493
Operating expense:
Pharmacy operations	3,648	3,085	7,578	5,678
General and administrative	6,100	5,737	12,642	11,413
Selling and marketing	2,307	1,613	4,612	3,147
Research and development	281	201	774	369
Total operating expense	12,336	10,636	25,606	20,607
Operating loss	(11,418)	(10,463)	(24,187)	(20,114)
Total pharmacy and hardware revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	10,930	4,725	19,944	8,506
Total cost of products sold and services	10,151	4,679	18,714	8,205
Retail pharmacy revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	10,641	4,494	19,490	7,912
Hardware
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	180	123	236	364
Subscription
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	109	108	218	230
Total service revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	254	305	354	551
Total cost of products sold and services	115	178	165	359
Software
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	86	41	133	74
Maintenance and support
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	47	40	79	71
Installation
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	71	12	77	28
Professional services and other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	50	212	65	378
Retail Pharmacy Services
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	10,641	4,494	19,490	7,912
Total cost of products sold and services	9,930	4,435	18,412	7,764
Operating expense:	711	59	1,078	148
Retail Pharmacy Services | Total pharmacy and hardware revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	10,641	4,494	19,490	7,912
Retail Pharmacy Services | Retail pharmacy revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	10,641	4,494	19,490	7,912
Retail Pharmacy Services | Hardware
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Retail Pharmacy Services | Subscription
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Retail Pharmacy Services | Total service revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Retail Pharmacy Services | Software
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Retail Pharmacy Services | Maintenance and support
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Retail Pharmacy Services | Installation
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Retail Pharmacy Services | Professional services and other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Pharmacy Technology
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	543	536	808	1,145
Total cost of products sold and services	336	422	467	800
Operating expense:	207	114	341	345
Pharmacy Technology | Total pharmacy and hardware revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	289	231	454	594
Pharmacy Technology | Retail pharmacy revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	0	0	0	0
Pharmacy Technology | Hardware
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	180	123	236	364
Pharmacy Technology | Subscription
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	109	108	218	230
Pharmacy Technology | Total service revenue
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	254	305	354	551
Pharmacy Technology | Software
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	86	41	133	74
Pharmacy Technology | Maintenance and support
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	47	40	79	71
Pharmacy Technology | Installation
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	71	12	77	28
Pharmacy Technology | Professional services and other
Segment Reporting, Revenue Reconciling Item [Line Items]
Total revenue	$ 50	$ 212	$ 65	$ 378

REVENUE AND SEGMENT REPORTING_3

REVENUE AND SEGMENT REPORTING - Schedule of Assets and Liabilities by Segment (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 52,833	$ 38,143
Liabilities	20,046	19,070
Operating Segments | Retail Pharmacy Services
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	16,253	13,641
Liabilities	6,462	5,618
Operating Segments | Pharmacy Technology
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	8,335	5,222
Liabilities	3,404	3,567
Corporate
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	28,245	19,280
Liabilities	$ 10,180	$ 9,885

REVENUE AND SEGMENT REPORTING_4

REVENUE AND SEGMENT REPORTING - Long-Lived Assets by Geographic Area (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Segment Reporting, Asset Reconciling Item [Line Items]
Total long-lived assets	$ 8,799	$ 8,230
United States
Segment Reporting, Asset Reconciling Item [Line Items]
Total long-lived assets	8,365	7,675
Canada
Segment Reporting, Asset Reconciling Item [Line Items]
Total long-lived assets	$ 434	$ 555